How to buy ALX Oncology stock | $56.56

ALX Oncology Holdings Inc is a biotechnology business based in the US. ALX Oncology shares (ALXO) are listed on the NASDAQ and all prices are listed in US Dollars. ALX Oncology employs 24 staff and has a trailing 12-month revenue of around 0.00.

ALX Oncology stock price (NASDAQ: ALXO)

Use our graph to track the performance of ALXO stocks over time.

ALX Oncology shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$56.56
52-week range	$29.06 - $110.00
50-day moving average	$56.65
200-day moving average	$67.74
Wall St. target price	$97.29
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.74

Buy ALX Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy ALX Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ALX Oncology Holdings Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ALX Oncology price performance over time

Historical closes compared with the close of $56.56 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	3.44%
3 months (2021-04-30)	-9.74%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

ALX Oncology financials

Revenue TTM	$527,000
Gross profit TTM	$107,000
Return on assets TTM	-12.15%
Return on equity TTM	-21.05%
Profit margin	0%
Book value	$10.41
Market capitalisation	$2.4 billion

TTM: trailing 12 months

Shorting ALX Oncology shares

There are currently 2.1 million ALX Oncology shares held short by investors – that's known as ALX Oncology's "short interest". This figure is 1.7% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting ALX Oncology shares can be evaluated.

ALX Oncology's "short interest ratio" (SIR)

ALX Oncology's "short interest ratio" (SIR) is the quantity of ALX Oncology shares currently shorted divided by the average quantity of ALX Oncology shares traded daily (recently around 195858.64374403). ALX Oncology's SIR currently stands at 10.47. In other words for every 100,000 ALX Oncology shares traded daily on the market, roughly 10470 shares are currently held short.

However ALX Oncology's short interest can also be evaluated against the total number of ALX Oncology shares, or, against the total number of tradable ALX Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ALX Oncology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 ALX Oncology shares in existence, roughly 50 shares are currently held short) or 0.1193% of the tradable shares (for every 100,000 tradable ALX Oncology shares, roughly 119 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against ALX Oncology.

Find out more about how you can short ALX Oncology stock.

ALX Oncology share dividends

We're not expecting ALX Oncology to pay a dividend over the next 12 months.

ALX Oncology overview

ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc.

Frequently asked questions

What percentage of ALX Oncology is owned by insiders or institutions?
Currently 14.478% of ALX Oncology shares are held by insiders and 84.153% by institutions. How many people work for ALX Oncology?
Latest data suggests 24 work at ALX Oncology. When does the fiscal year end for ALX Oncology?
ALX Oncology's fiscal year ends in December. Where is ALX Oncology based?
ALX Oncology's address is: 866 Malcolm Road, Burlingame, CA, United States, 94010 What is ALX Oncology's ISIN number?
ALX Oncology's international securities identification number is: US00166B1052